Insights from ESMO Breast 2024 Annual Meeting


 

ESMO Breast 2024 Insights: "CAPItello-291 Trial PFS2 & TFSC Updates - Capivasertib & Fulvestrant for Patients With Aromatase Inhibitor-Resistant HR+/HER2- Advanced BC"

336 views
May 22, 2024
Comments 0
Login to view comments. Click here to Login